Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Affiliations

• 1 Biogen, Cambridge, MA, USA. tien.dam@biogen.com.
• 2 Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
• 3 Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
• 4 Department of Neurology, Technische Universität München, Munich, Germany.
• 5 German Center for Neurodegenerative Diseases, Munich, Germany.
• 6 Department of Neurology, Hanover Medical School, Hanover, Germany.
• 7 National Hospital for Neurology and Neurosurgery, London, UK.
• 8 University of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA.
• 9 Edmond J. Safra Program in Parkinson's Disease and the Rossy PSP Centre, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada.
• 10 Sorbonne Université, Assistance Publique Hôpitaux de Paris, INSERM, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, Hôpital Pitié-Salpêtrière, Paris, France.
• 11 Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.
• 12 Global R&D Partners, LLC, San Diego, CA, USA.
• 13 Biogen, Cambridge, MA, USA.